Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the 12 Best Growth Stocks Trading in Oversold Territory.
On May 20, Roivant Sciences reported its financial results for FQ4 and the full year FY2026, alongside a comprehensive business update
The company finished the year with $4.3 billion in consolidated cash and marketable securities, providing a runway into profitability. A significant highlight was a $2.25 billion global settlement reached with Moderna, concluding pending patent-infringement litigation. In its clinical portfolio, Roivant reported positive results for IMVT-1402 in difficult-to-treat rheumatoid arthritis, with further updates expected later this year.
Additionally, brepocitinib received Breakthrough Therapy Designation for cutaneous sarcoidosis, and its commercial launch for dermatomyositis is scheduled for late September 2026. Topline data for several other programs, including studies in non-infectious uveitis and pulmonary hypertension, are also anticipated in H2 2026. CEO Matt Gline expressed confidence in the company’s momentum, emphasizing the potential of their differentiated pipeline to address significant patient needs.